Clearmind Medicine publishes three US patent applications for LSD, ketamine, ibogaine combinations with PEA
CMND•Patent applications cover psychedelic combinations with PEA
Clearmind Medicine published three U.S. patent applications covering combinations of LSD, ketamine, ibogaine with N-acylethanolamines such as PEA.
Applications target potential treatments for depression, PTSD, pain, substance use disorders, aiming for lower doses with maintained efficacy.
Publications expand IP from its collaboration with NeuroThera Labs, integrating PEA technology into psychedelic-derived therapeutic programs.
